Deliver your therapeutics across the BBB with genO-hTFRC mice

Lundbeck has demonstrated that the genO-hTFRC model can be used to assess the efficacy of antibodies that target proteins expressed in brain cells, such as BACE1.

Efficacy assessment of anti-BACE1 or anti-TFRC/anti-BACE1 antibodies in genO-hTFRC mice

Adapted from Sônego et al., poster presented at AACR 2024

‍

What sets the genO-hTFRC mouse model apart?

  • Physiological regulation and expression pattern of human TFRC
  • Lack of expression of the murine target gene
  • Fully functional mouse immune system
  • Available on C57BL/6N genetic background

Discover our catalog of genO-hTFRC models

In order to expand the range of applications of our genO-hTFRC mouse, this model has been intercrossed with several other models:‍

  • ‍genO-hTFRC/hFcγR — to increase the translatability of the efficacy assessment of Fc-dependent antibodies that target the CNS

Improve the delivery of therapeutics aiming to cross the blood-brain barrier with the genO-hTFRC mouse model

Get in touch about

Let us know how we can help

Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe